JP2013537891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537891A5 JP2013537891A5 JP2013528384A JP2013528384A JP2013537891A5 JP 2013537891 A5 JP2013537891 A5 JP 2013537891A5 JP 2013528384 A JP2013528384 A JP 2013528384A JP 2013528384 A JP2013528384 A JP 2013528384A JP 2013537891 A5 JP2013537891 A5 JP 2013537891A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- composition
- cyclodextrins
- aspirin
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38209810P | 2010-09-13 | 2010-09-13 | |
| US61/382,098 | 2010-09-13 | ||
| PCT/US2011/051386 WO2012037117A1 (en) | 2010-09-13 | 2011-09-13 | Aqueous drug delivery system comprising off - flavor masking agent |
| US13/231,150 | 2011-09-13 | ||
| US13/231,150 US9018193B2 (en) | 2010-09-13 | 2011-09-13 | Aqueous drug delivery system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016029886A Division JP6263699B2 (ja) | 2010-09-13 | 2016-02-19 | 不快味マスキング剤を有する水性薬物送達システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537891A JP2013537891A (ja) | 2013-10-07 |
| JP2013537891A5 true JP2013537891A5 (enExample) | 2014-11-06 |
| JP5890951B2 JP5890951B2 (ja) | 2016-03-22 |
Family
ID=44674918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528384A Expired - Fee Related JP5890951B2 (ja) | 2010-09-13 | 2011-09-13 | 不快味マスキング剤を有する水性薬物送達システム |
| JP2016029886A Expired - Fee Related JP6263699B2 (ja) | 2010-09-13 | 2016-02-19 | 不快味マスキング剤を有する水性薬物送達システム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016029886A Expired - Fee Related JP6263699B2 (ja) | 2010-09-13 | 2016-02-19 | 不快味マスキング剤を有する水性薬物送達システム |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9018193B2 (enExample) |
| EP (2) | EP3210597A1 (enExample) |
| JP (2) | JP5890951B2 (enExample) |
| KR (1) | KR20140007798A (enExample) |
| CN (1) | CN103209684A (enExample) |
| AU (1) | AU2011302293B2 (enExample) |
| BR (1) | BR112013005987A2 (enExample) |
| CA (1) | CA2811202A1 (enExample) |
| IL (1) | IL225149B (enExample) |
| MY (1) | MY162175A (enExample) |
| NZ (1) | NZ608239A (enExample) |
| PH (1) | PH12013500477A1 (enExample) |
| RU (1) | RU2013116336A (enExample) |
| SG (2) | SG10201507554RA (enExample) |
| WO (1) | WO2012037117A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150328246A1 (en) * | 2014-05-16 | 2015-11-19 | Vivus, Inc. | Orally administratable formulations for the controlled release of a pharmacologically active agent |
| US11623008B2 (en) * | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
| CN114903134A (zh) * | 2014-12-09 | 2022-08-16 | 以西结·戈兰 | 酒精饮料替代品 |
| EP3705469A1 (en) | 2014-12-09 | 2020-09-09 | GOLAN, Ezekiel | Binge behavior regulators |
| TWI714568B (zh) * | 2015-04-07 | 2021-01-01 | 日商日產化學工業股份有限公司 | 液狀培養基組成物的製造方法，及用於該製造方法之製造裝置與套組 |
| US10493083B2 (en) | 2015-10-30 | 2019-12-03 | Cmp Development Llc | Spironolactone aqueous compositions |
| US20210290524A1 (en) * | 2016-09-06 | 2021-09-23 | Children's Medical Center Corporation | Topical trpv1 antagonists and methods and compositions thereof |
| EP3512511A4 (en) * | 2016-09-16 | 2020-05-20 | Cydex Pharmaceuticals, Inc. | FORMULATIONS WITH ACETAMINOPHENS AND SULFOALKYL ETHER-CYCLODEXTRIN |
| EP3740193A4 (en) * | 2018-01-15 | 2022-03-02 | Seattle Gummy Company | SEMI-SOLID ANTHIHISTAMINE COMPOSITIONS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| US10828286B2 (en) * | 2018-05-24 | 2020-11-10 | Gm Pharmaceuticals, Inc. | Niacin and berberine compositions and methods of use thereof |
| SG11202013126QA (en) * | 2018-06-29 | 2021-02-25 | Roquette Freres | NOVEL HYDROXYPROPYL-ß-CYCLODEXTRIN AND PROCESS FOR THE PRODUCTION THEREOF |
| JP2020019731A (ja) * | 2018-07-31 | 2020-02-06 | 日本食品化工株式会社 | アムロジピンベシル酸塩の苦味抑制剤 |
| JP6711875B2 (ja) * | 2018-08-29 | 2020-06-17 | 日本食品化工株式会社 | マクロライド化合物の苦味抑制剤 |
| US20210401017A1 (en) * | 2020-12-11 | 2021-12-30 | Jiangnan University | Preparation Method of Starch-based Double Emulsion Embedding Fat-soluble Functional Factors |
| US11452690B1 (en) * | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
| GR1010732B (el) * | 2023-06-02 | 2024-07-25 | Ιουλια Κλεωνος Τσετη | Φαρμακευτικη συνθεση ιβουπροφαινης και παρακεταμολης για απο του στοματος χορηγηση |
| CN119185191A (zh) * | 2024-09-12 | 2024-12-27 | 广东心宝药业科技有限公司 | 一种口服液药物口感的控制方法及系统 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| FR2647343B1 (fr) * | 1989-05-24 | 1994-05-06 | Rhone Poulenc Sante | Nouvelle forme pharmaceutique poreuse et sa preparation |
| GB9226391D0 (en) | 1992-12-18 | 1993-02-10 | Cpc International Inc | Xanthan gelling agents |
| US5362860A (en) | 1993-02-01 | 1994-11-08 | Warner-Lambert Company | Neutral stabilization complex for CI-979 HCl, a cognition activator |
| FR2704146B1 (fr) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
| US5651980A (en) | 1994-04-15 | 1997-07-29 | Biohybrid Technologies, Inc. | Methods of use of uncoated gel particles |
| US6319535B1 (en) | 1995-11-28 | 2001-11-20 | Laurence J. Shaw | Confections that “swim” in a carbonated beverage |
| AU733927B2 (en) | 1996-10-09 | 2001-05-31 | Givaudan-Roure (International) Sa | Process for preparing beads as food additive |
| EP0946197A1 (en) | 1996-11-29 | 1999-10-06 | Monsanto Company | Lubricious self-standing (intact) gel for oral delivery of biologically-active ingredients |
| US5776431A (en) | 1997-03-26 | 1998-07-07 | Galat; Alexander | Water-soluble aspirin composition |
| DE69836207T2 (de) | 1997-03-28 | 2007-08-30 | Eisai Co., Ltd. | Orale pharmazeutische zusammensetzungen mit reduzierter bitterkeit durch geschmacksmaskiermittel |
| BE1011251A3 (fr) | 1997-07-03 | 1999-06-01 | Ucb Sa | Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine. |
| WO1999003474A1 (de) | 1997-07-15 | 1999-01-28 | Walter Burghart | Verfahren zum herstellen von stabilen acetylsalicylsäure-lösungen |
| WO1999022768A1 (en) | 1997-10-31 | 1999-05-14 | Monsanto Company | Controlled release compositions comprising gellan gum gels |
| US6572898B2 (en) | 1999-05-21 | 2003-06-03 | Pts Labs Llc | Electrolyte gels for maintaining hydration and rehydration |
| SK282717B6 (sk) | 2000-03-10 | 2002-11-06 | �Stav Experiment�Lnej Farmakol�Gie Sav | Spôsob prípravy ultravysokomolekulových hyalurónanov |
| RU2003114297A (ru) | 2000-10-16 | 2004-11-27 | Пепсико, Инк. (Us) | Напитки, обогащенные кальцием, и способ их производства |
| US7141555B2 (en) | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US7494669B2 (en) | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| MXPA04008173A (es) * | 2002-02-22 | 2004-11-26 | Pharmacia Corp | Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio. |
| US20090215735A1 (en) * | 2002-02-25 | 2009-08-27 | Alcon, Inc. | Topical solution formulations containing a corticosteroid and a cyclodextrin |
| EP1488812A4 (en) | 2002-03-04 | 2006-05-03 | Medrx Co Ltd | PHASE TRANSFER OF LIVING MATERIAL IN VIVO AND LIQUID ORAL PREPARATIONS |
| AU2003246489A1 (en) | 2002-07-19 | 2004-02-09 | Vitalstate Canada Ltd. | Oral delivery system containing a gel matrix and liposomes |
| ATE487470T1 (de) | 2002-09-11 | 2010-11-15 | Elan Pharma Int Ltd | Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse |
| US20060018972A1 (en) | 2002-11-26 | 2006-01-26 | Upm Pharmaceuticals, Inc. | Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| US7160565B2 (en) | 2003-03-31 | 2007-01-09 | Breakthru Products, Llc | Hydration beverage and method of delivering nutrients |
| KR101059057B1 (ko) | 2003-09-12 | 2011-08-24 | 류가쿠산 가부시키가이샤 | 쓴맛을 차단할 수 있는 과립상 젤리 음료 |
| WO2005037264A1 (ja) | 2003-10-17 | 2005-04-28 | Medrx Co., Ltd. | ビグアナイド系薬剤を含有するゼリー製剤 |
| IL160095A0 (en) | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
| WO2006004574A2 (en) * | 2004-02-19 | 2006-01-12 | Abbott Laboratories | Method for using gamma cyclodextrin to control blood glucose and insulin secretion |
| EP2258349B1 (en) | 2004-05-11 | 2014-07-16 | Egalet Ltd. | Swellable dosage form comprising gellan gum |
| US20080044481A1 (en) | 2004-05-27 | 2008-02-21 | Mordechai Harel | Microparticles for Oral Delivery |
| BRPI0513455A (pt) | 2004-07-22 | 2008-05-06 | Pfizer Prod Inc | formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada |
| US20070092561A1 (en) | 2005-06-24 | 2007-04-26 | Don Milne | Water-Soluble Aspirin Composition |
| US8715731B2 (en) | 2006-03-22 | 2014-05-06 | Isp Investments Inc. | Process of reducing the bitter taste of water soluble actives by co-grinding the active with β cyclodextrin |
| PT103476B (pt) | 2006-05-10 | 2008-09-19 | Univ De Coimbra | Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil |
| CA2686927A1 (en) | 2006-07-06 | 2008-01-06 | Abbott Respiratory Llc | Superporous hydrogels for heavy-duty applications |
| WO2008007383A1 (en) | 2006-07-14 | 2008-01-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dried electrified hydrocolloid gels having unique structure and porosity |
| WO2008012329A2 (en) | 2006-07-28 | 2008-01-31 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
| GB0616794D0 (en) * | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
| JP5205909B2 (ja) * | 2006-10-18 | 2013-06-05 | 大正製薬株式会社 | 粘膜適用液剤 |
| JP5048398B2 (ja) * | 2007-06-13 | 2012-10-17 | 大蔵製薬株式会社 | 抗真菌剤の医薬組成物 |
| WO2009082203A1 (en) | 2007-12-20 | 2009-07-02 | N.V. Nutricia | Liquid nucleotides/nucleosides-containing product |
| WO2009008006A2 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
| KR100937625B1 (ko) | 2007-08-10 | 2010-01-20 | 주식회사 제닉 | 가용성 웹 공극필름 및 이의 제조방법 |
| US9186640B2 (en) | 2007-08-28 | 2015-11-17 | Pepsico, Inc. | Delivery and controlled release of encapsulated lipophilic nutrients |
| WO2009084017A2 (en) * | 2007-10-10 | 2009-07-09 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
| DK2201956T3 (da) | 2007-10-12 | 2014-07-14 | Ryukakusan Co Ltd | Kornformet geleret drikkevare til medicinering og fremgangsmåde til fremstilling af samme |
| US20090104251A1 (en) | 2007-10-22 | 2009-04-23 | Sensient Flavors Inc. | Heat stable microcapsules and methods for making and using the same |
| US8563066B2 (en) * | 2007-12-17 | 2013-10-22 | New World Pharmaceuticals, Llc | Sustained release of nutrients in vivo |
| ES2402753T3 (es) | 2008-02-06 | 2013-05-08 | University Of East Anglia | Composición y método para ayudar a la deglución |
| MX2010011545A (es) | 2008-04-21 | 2011-04-11 | Otonomy Inc | Formulaciones para tratar enfermedades y afecciones del oido. |
| US8791064B2 (en) | 2008-04-24 | 2014-07-29 | Technion Research And Development Foundation Ltd. | Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive compounds |
| GB0813929D0 (en) | 2008-07-30 | 2008-09-03 | Glaxo Group Ltd | Novel method |
| US9414615B2 (en) * | 2010-01-18 | 2016-08-16 | PepciCo, Inc. | Gel-based compositions and methods of making same |
-
2011
- 2011-09-13 SG SG10201507554RA patent/SG10201507554RA/en unknown
- 2011-09-13 JP JP2013528384A patent/JP5890951B2/ja not_active Expired - Fee Related
- 2011-09-13 RU RU2013116336/15A patent/RU2013116336A/ru unknown
- 2011-09-13 US US13/231,150 patent/US9018193B2/en active Active
- 2011-09-13 BR BR112013005987A patent/BR112013005987A2/pt not_active IP Right Cessation
- 2011-09-13 MY MYPI2013700400A patent/MY162175A/en unknown
- 2011-09-13 PH PH1/2013/500477A patent/PH12013500477A1/en unknown
- 2011-09-13 KR KR1020137009449A patent/KR20140007798A/ko not_active Ceased
- 2011-09-13 WO PCT/US2011/051386 patent/WO2012037117A1/en not_active Ceased
- 2011-09-13 EP EP16186439.2A patent/EP3210597A1/en not_active Withdrawn
- 2011-09-13 CA CA2811202A patent/CA2811202A1/en not_active Abandoned
- 2011-09-13 SG SG2013017991A patent/SG188509A1/en unknown
- 2011-09-13 AU AU2011302293A patent/AU2011302293B2/en not_active Ceased
- 2011-09-13 NZ NZ608239A patent/NZ608239A/en not_active IP Right Cessation
- 2011-09-13 CN CN2011800546354A patent/CN103209684A/zh active Pending
- 2011-09-13 EP EP11760656.6A patent/EP2616046B1/en active Active
-
2013
- 2013-03-10 IL IL225149A patent/IL225149B/en not_active IP Right Cessation
-
2015
- 2015-03-30 US US14/672,337 patent/US9789191B2/en not_active Expired - Fee Related
-
2016
- 2016-02-19 JP JP2016029886A patent/JP6263699B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-17 US US15/786,217 patent/US20180256725A1/en not_active Abandoned
-
2019
- 2019-10-21 US US16/658,524 patent/US20200114011A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537891A5 (enExample) | ||
| AU2024227357A1 (en) | Ganaxolone For Use In Treating Genetic Epileptic Disorders | |
| JP2014528474A5 (enExample) | ||
| JP5589130B1 (ja) | 結晶及び該結晶を含有してなる医薬製剤 | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| JP2015524444A5 (enExample) | ||
| EA201290026A1 (ru) | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) | |
| JP6456533B2 (ja) | ロキソプロフェン含有外用剤組成物 | |
| JP2008044951A5 (enExample) | ||
| JP2012530723A5 (enExample) | ||
| Lehrer-Graiwer et al. | GBT440, a potent anti-sickling hemoglobin modifier reduces hemolysis, improves anemia and nearly eliminates sickle cells in peripheral blood of patients with sickle cell disease | |
| Saini et al. | Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review | |
| JP2010515682A5 (enExample) | ||
| JP5842058B2 (ja) | 自閉症の治療における使用のためのクレンブテロール | |
| TW201034674A (en) | Uses of NK receptor antagonists | |
| Bavbek et al. | Recurrent hyponatremia associated with citalopram and mirtazapine | |
| Brown et al. | GBT021601, a next generation HbS polymerization inhibitor: results of safety, tolerability, pharmacokinetics and pharmacodynamics in adults living with sickle cell disease and healthy volunteers | |
| Garnock-Jones | Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine | |
| JP5815273B2 (ja) | 抗炎症剤組成物 | |
| CN102716120B (zh) | (3r)-去-o-甲基毛狄泼老素在制备预防或治疗抑郁症的药物中的用途 | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| TW200831072A (en) | Non-steroidal anti-inflammatory drugs for cough | |
| WO2015166419A2 (es) | Proceso de obtención y composición farmacéutica de ketorolaco trometamina y clorhidrato de tramadol sublingual usado para el dolor | |
| JP6178058B2 (ja) | 抗炎症及び／又は抗ヒスタミン剤組成物 | |
| CN117715633A (zh) | 用于治疗covid-19、自身免疫性疾病或细胞因子风暴反应的利多卡因或阿替卡因 |